Literature DB >> 8043072

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

M R Law1, N J Wald, S G Thompson.   

Abstract

OBJECTIVE: To estimate by how much and how quickly a given reduction in serum cholesterol concentration will reduce the risk of ischaemic heart disease.
DESIGN: Data on the incidence of ischaemic heart disease and serum cholesterol concentration were analysed from 10 prospective (cohort) studies, three international studies in different communities, and 28 randomised controlled trials (with mortality data analysed according to allocated treatment to ensure the avoidance of bias). MAIN OUTCOME MEASURE: Decrease in incidence of ischaemic heart disease or mortality for a 0.6 mmol/l (about 10%) decrease in serum cholesterol concentration.
RESULTS: For men results from the cohort studies showed that a decrease of serum cholesterol concentration of 0.6 mmol/l (about 10%) was associated with a decrease in incidence of ischaemic heart disease of 54% at age 40 years, 39% at age 50, 27% at 60, 20% at 70, and 19% at 80. The combined estimate from the three international studies (for ages 55-64 years) was 38% (95% confidence interval 33% to 42%), somewhat greater than the cohort study estimate of 27%. The reductions in incidence of ischaemic heart disease in the randomised trials (for ages 55-64 years) were 7% (0 to 14%) in the first two years, 22% (15% to 28%) from 2.1-5 years, and 25% (15% to 35%) after five years, the last estimate being close to the estimate of 27% for the long term reduction from the cohort studies. The data for women are limited but indicate a similar effect.
CONCLUSIONS: The results from the cohort studies, international comparisons, and clinical trials are remarkably consistent. The cohort studies, based on half a million men and 18,000 ischaemic heart disease events, estimate that a long term reduction in serum cholesterol concentration of 0.6 mmol/l (10%), which can be achieved by moderate dietary change, lowers the risk of ischaemic heart disease by 50% at age 40, falling to 20% at age 70. The randomised trials, based on 45,000 men and 4000 ischaemic heart disease events show that the full effect of the reduction in risk is achieved by five years.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043072      PMCID: PMC2539460          DOI: 10.1136/bmj.308.6925.367

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  48 in total

1.  Clinical studies of long-term estrogen therapy in men with mvocardial infarction.

Authors:  J MARMORSTON; F J MOORE; C E HOPKINS; O T KUZMA; J WEINER
Journal:  Proc Soc Exp Biol Med       Date:  1962-06

2.  Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group.

Authors:  J D Neaton; D Wentworth
Journal:  Arch Intern Med       Date:  1992-01

3.  Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART).

Authors:  M L Burr; A M Fehily; J F Gilbert; S Rogers; R M Holliday; P M Sweetnam; P C Elwood; N M Deadman
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

4.  Running out of staff for the NHS.

Authors:  B Livesley
Journal:  BMJ       Date:  1989-07-01

5.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

6.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

Authors:  H Buchwald; R L Varco; J P Matts; J M Long; L L Fitch; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink
Journal:  N Engl J Med       Date:  1990-10-04       Impact factor: 91.245

7.  Cancer incidence and cancer mortality in relation to serum cholesterol.

Authors:  S A Törnberg; L E Holm; J M Carstensen; G A Eklund
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

8.  Serum cholesterol and mortality among Japanese-American men. The Honolulu (Hawaii) Heart Program.

Authors:  G N Stemmermann; P H Chyou; A Kagan; A M Nomura; K Yano
Journal:  Arch Intern Med       Date:  1991-05

9.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.

Authors:  R H Bradford; C L Shear; A N Chremos; C Dujovne; M Downton; F A Franklin; A L Gould; M Hesney; J Higgins; D P Hurley
Journal:  Arch Intern Med       Date:  1991-01

10.  Cholesterol and coronary heart disease mortality. A 23-year follow-up study of 9902 men in Israel.

Authors:  U Goldbourt; S Yaari
Journal:  Arteriosclerosis       Date:  1990 Jul-Aug
View more
  227 in total

Review 1.  Exploring a fiscal food policy: the case of diet and ischaemic heart disease.

Authors:  T Marshall
Journal:  BMJ       Date:  2000-01-29

2.  Plant sterol and stanol margarines and health.

Authors:  M Law
Journal:  BMJ       Date:  2000-03-25

3.  Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reduction?

Authors:  S Ramachandran; J M French; M P Vanderpump; P Croft; R H Neary
Journal:  BMJ       Date:  2000-03-11

Review 4.  What is the optimal age for starting lipid lowering treatment? A mathematical model.

Authors:  S Ulrich; A D Hingorani; J Martin; P Vallance
Journal:  BMJ       Date:  2000-04-22

5.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

6.  Lean Red Meat and Lean White Meat in the NCEP Step I Diet.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

7.  Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.

Authors:  W G Simpson; P Twomey
Journal:  BMJ       Date:  2000-09-09

Review 8.  What is the "golden standard" for assessing population-based interventions?--problems of dilution bias.

Authors:  L Lindholm; M Rosén
Journal:  J Epidemiol Community Health       Date:  2000-08       Impact factor: 3.710

Review 9.  Plant sterol and stanol margarines and health.

Authors:  M R Law
Journal:  West J Med       Date:  2000-07

10.  Risk in cardiovascular disease. Merit of using risk reduction rather than absolute risk for lipid lowering drugs.

Authors:  R Neary; S Ramachandran
Journal:  BMJ       Date:  2000-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.